ENZON PHARMACEUTICALS INC
ENZN
ENZN was delisted on the 19th of May, 2016.
65 hedge funds and large institutions have $24.7M invested in ENZON PHARMACEUTICALS INC in 2014 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 15 increasing their positions, 25 reducing their positions, and 12 closing their positions.
5% more capital invested
Capital invested by funds: $23.4M → $24.7M (+$1.25M)
3% less funds holding
Funds holding: 67 → 65 (-2)
17% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 12
40% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 25
67% less call options, than puts
Call options by funds: $7K | Put options by funds: $21K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CSC
Cove Street Capital
El Segundo,
California
|
+$879K |
| 2 |
Schroder Investment Management Group
London,
United Kingdom
|
+$653K |
| 3 |
Renaissance Technologies
New York
|
+$562K |
| 4 |
NFA
Nationwide Fund Advisors
Columbus,
Ohio
|
+$343K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$292K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MFP
Michael F. Price
|
-$504K |
| 2 |
Northern Trust
Chicago,
Illinois
|
-$362K |
| 3 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$329K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$314K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$226K |
ENZN Hedge Fund Activity: Q3 2014 in Review
65 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in ENZON PHARMACEUTICALS INC (ENZN) for Q3 2014, worth a combined $24.7M — up 5.3% from $23.4M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of ENZN and 10 opened new positions — a net loss of 2 holders — while 25 trimmed existing stakes and 15 added.
The largest buyer was Cove Street Capital, opening a new position worth an estimated $879K. The largest seller was Michael F. Price, cutting an estimated $504K.
- 65 institutional investors held ENZON PHARMACEUTICALS INC (ENZN) as of Q3 2014, down from 67 in Q2 2014.
- Funds reported $24.7M of ENZON PHARMACEUTICALS INC stock for Q3 2014, up 5.3% quarter-over-quarter.
- 10 funds opened new ENZON PHARMACEUTICALS INC positions in Q3 2014 and 12 closed out, a net change of -2 holders.
- The largest ENZON PHARMACEUTICALS INC buyer in Q3 2014 was Cove Street Capital, an estimated $879K added.
- The largest ENZON PHARMACEUTICALS INC seller in Q3 2014 was Michael F. Price, an estimated $504K sold.
Based on aggregated 13F filings for Q3 2014.